SurroMed to use Bruker Daltonics mass spectrometers and collaborate on development of instruments, software, and reagents for biomarker discovery
Bruker Daltonics and SurroMed have announced a strategic partnership that includes SurroMed acquisition of multiple Bruker Daltonics Microtof ESI-Tof mass spectrometers for use in SurroMed's biomarker discovery laboratory, as well as collaboration on development of advanced software and sample fractionation products.
"The new Bruker Daltonics Microtof provides the highest resolution and mass accuracy of any benchtop ESI-Tof machine available today.
"In conjunction with SurroMed's proprietary MassView software, these instruments will allow us to increase substantially the number of proteins, peptides and metabolites that we are able to identify and quantify from our samples," said Christopher Becker, SurroMed's director of chemistry.
"We are very pleased to be collaborating with SurroMed, a pioneer and leader in biomarker discovery," stated Frank Laukien, president and CEO of Bruker Daltonics.
"The high performance of our Microtof is well suited for SurroMed's protein and metabolite biomarker profiling methods using LC/MS with high mass accuracy.
"In addition, the instruments are robust enough to satisfy the high-throughput requirements of SurroMed's Biomarker discovery laboratory.
"Collaborating with SurroMed on the further development of LC-ESI/Tof based biomarker discovery tools adds an important second dimension to our strategy as a leading tools provider for clinical proteomics".
"We are delighted to establish this strategic relationship with Bruker Daltonics," added Gordon Ringold, chairman and CEO of SurroMed.
"We look forward to collaborating on Bruker Daltonics's development of leading edge mass spectrometry and sample fractionation products, as well as on advanced bioinformatics software for mass spectrometry based biomarker discovery.
"Having access to the most advanced analysis tools should further our goal of being the leading biomarker drug and diagnostics discovery company."
